Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vertex Pharmaceuticals, a biotechnology company, has appointed Matthew Emmens as its new president. In addition, the company also announced that he will transition to president, CEO and chairman in May 2009 upon Joshua Boger's retirement.
Subscribe to our email newsletter
Mr Emmens has been a Vertex director since 2004, and previously served as CEO of Astra Merck, and of Shire, where he continues as chairman. Dr Boger, who founded Vertex in 1989, will retire from his position as CEO of Vertex on May 23, 2009.
Dr Boger and Mr Emmens will work closely together during the leadership transition period. Charles Sanders, Vertex’s chairman, will remain as lead director on Vertex’s board, following Mr Emmens’s appointment as chairman. Dr Boger will also remain an active member of the board.
Mr Emmens said: “It is a great privilege to be asked to lead Vertex at this important time in the Company’s evolution. I look forward to working with Joshua to enable a smooth transition as the Company prepares for its next stage of growth, and the commercial launch of important medicines for serious diseases. We have a rare opportunity to create a world class commercial enterprise that complements Vertex’s excellence in R&D innovation.”